Oncology pp 1372-1409 | Cite as

Infectious Complications of Cancer Therapy

  • Nasia Safdar
  • Christopher J. Crnich
  • Dennis G. Maki


Advances in the management of cancer, particularly the development of new chemotherapeutic agents, have greatly improved the survival and outcome of patients with hematologic malignancies and solid tumors; overall 5-year survival rates in cancer patients have improved from 39% in the 1960s to 60% in the 1990s.1 However, infection, caused by both the underlying malignancy and cancer chemotherapy, particularly myelosuppressive chemotherapy, remains a persistent challenge.


Respiratory Syncytial Virus Clin Infect Invasive Aspergillosis Invasive Fungal Infection Febrile Neutropenic Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Rolston KVI, Bodey GP. Infections in patients with cancer. In: Frei E (ed) Cancer Medicine. Hamilton, Ontario: Decker, 2003.Google Scholar
  2. 2.
    Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer (Phila) 2004;100:228–237.PubMedGoogle Scholar
  3. 3.
    Casazza AR, Duvall CP, Carbone PP. Infection in lymphoma. Histology, treatment, and duration in relation to incidence and survival. JAMA 1966;197:710–716.PubMedGoogle Scholar
  4. 4.
    Bodey GP. Infection in cancer patients. A continuing association. Am J Med 1986;81:11–26.PubMedGoogle Scholar
  5. 6.
    Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730–751.PubMedGoogle Scholar
  6. 7.
    Egerer G, Hensel M, Ho AD. Infectious complications in chronic lymphoid malignancy. Curr Treat Options Oncol 2001;2:237–244.PubMedGoogle Scholar
  7. 8.
    Samonis G, Kontoyiannis DP. Infectious complications of purine analog therapy. Curr Opin Infect Dis 2001;14:409–413.PubMedGoogle Scholar
  8. 9.
    Anaissie EJ, Kontoyiannis DP, O’Brien S, et al. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 1998;129:559–566.PubMedGoogle Scholar
  9. 10.
    Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 2004;5:292–302.PubMedGoogle Scholar
  10. 11.
    Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.PubMedGoogle Scholar
  11. 12.
    Maness LJ, McSweeney PA. Treatment options for newly diagnosed patients with chronic myeloid leukemia. Curr Hematol Rep 2004;3:54–61.PubMedGoogle Scholar
  12. 13.
    Lamanna N, Weiss M. Treatment options for newly diagnosed patients with adult acute lymphoblastic leukemia. Curr Hematol Rep 2004;3:40–46.PubMedGoogle Scholar
  13. 14.
    Wade JC, Newton B, Flournoy N, Meyers JD. Oral acyclovir for prevention of herpes simplex virus reactivation after marrow transplantation. Ann Intern Med 1984;100:823–828.PubMedGoogle Scholar
  14. 15.
    Chang HY, Rodriguez V, Narboni G, Bodey GP, Luna MA, Freireich EJ. Causes of death in adults with acute leukemia. Medicine (Baltim) 1976;55:259–268.PubMedGoogle Scholar
  15. 16.
    Feld R, Bodey GP, Rodriguez V, Luna M. Causes of death in patients with malignant lymphoma. Am J Med Sci 1974;268:97–106.PubMedGoogle Scholar
  16. 17.
    Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis 1999;29:490–494.PubMedGoogle Scholar
  17. 18.
    Rolston KVI, Bodey GP. Infections in patients with cancer. In: Holland JF, Frei E (eds) Cancer Medicine. Hamilton, Ontario: Decker, 2000.Google Scholar
  18. 19.
    Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 2003;36:1103–1110.PubMedGoogle Scholar
  19. 20.
    Anonymous. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990–May 1999, issued June 1999. Am J Infect Control 1999;27:520–532.Google Scholar
  20. 21.
    Farr BM. Vascular catheter related infections in cancer patients. Surg Oncol Clin N Am 1995;4:493–503.PubMedGoogle Scholar
  21. 22.
    Rupp ME, Fey PD. Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment. Drugs 2003;63:353–365.PubMedGoogle Scholar
  22. 23.
    Safdar N, Maki DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med 2002;136:834–844.PubMedGoogle Scholar
  23. 24.
    Endimiani A, Luzzaro F, Perilli M, et al. Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum beta-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin. Clin Infect Dis 2004;38:243–251.PubMedGoogle Scholar
  24. 25.
    Schimpff S, Satterlee W, Young VM, Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 1971;284:1061–1065.PubMedGoogle Scholar
  25. 26.
    Chatzinikolaou I, Abi-Said D, Bodey GP, Rolston KV, Tarrand JJ, Samonis G. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: Retrospective analysis of 245 episodes. Arch Intern Med 2000;160:501–509.PubMedGoogle Scholar
  26. 27.
    Pagano L, Tacconelli E, Tumbarello M, et al. Bacteremia in patients with hematological malignancies. Analysis of risk factors, etiological agents and prognostic indicators. Haematologica 1997;82:415–419.PubMedGoogle Scholar
  27. 28.
    Agger WA, Mardan A. Pseudomonas aeruginosa infections of intact skin. Clin Infect Dis 1995;20:302–308.PubMedGoogle Scholar
  28. 29.
    Rolston KV, Bodey GP. Pseudomonas aeruginosa infection in cancer patients. Cancer Invest 1992;10:43–59.PubMedGoogle Scholar
  29. 30.
    Carmeli Y, Troillet N, Karchmer AW, Samore MH. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med 1999;159:1127–1132.PubMedGoogle Scholar
  30. 31.
    Safdar N, Handelsman J, Maki DG. Does combination therapy reduce mortality in gram-negative bacteremia: a meta-analysis. In: 43rd InterScience Conference on Antimicrobial Agents and Chemotherapy, 2003.Google Scholar
  31. 32.
    Spanik S, Trupl J, Kunova A, et al. Risk factors, aetiology, therapy and outcome in 123 episodes of breakthrough bacteraemia and fungaemia during antimicrobial prophylaxis and therapy in cancer patients. J Med Microbiol 1997;46:517–523.PubMedGoogle Scholar
  32. 33.
    National Nosocomial Infections Surveillance (NNIS) System Report. Data summary from January 1992 to June 2002, issued August 2002. Am J Infect Control 2002;30:458–475.Google Scholar
  33. 34.
    Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH. Linezolid vs. vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003;124:1789–1797.PubMedGoogle Scholar
  34. 35.
    Tunkel AR, Sepkowitz KA. Infections caused by viridans streptococci in patients with neutropenia. Clin Infect Dis 2002;34:1524–1529.PubMedGoogle Scholar
  35. 36.
    Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis 1992;14:1201–1207.PubMedGoogle Scholar
  36. 37.
    Bilgrami S, Feingold JM, Dorsky D, Edwards RL, Clive J, Tutschka PJ. Streptococcus viridans bacteremia following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1998;21:591–595.PubMedGoogle Scholar
  37. 38.
    Cohen J, Donnelly JP, Worsley AM, Catovsky D, Goldman JM, Galton DA. Septicaemia caused by viridans streptococci in neutropenic patients with leukaemia. Lancet 1983;2:1452–1454.PubMedGoogle Scholar
  38. 39.
    Paganini H, Staffolani V, Zubizarreta P, Casimir L, Lopardo H, Luppino V. Viridans streptococci bacteraemia in children with fever and neutropenia: a case-control study of predisposing factors. Eur J Cancer 2003;39:1284–1289.PubMedGoogle Scholar
  39. 40.
    Ruescher TJ, Sodeifi A, Scrivani SJ, Kaban LB, Sonis ST. The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer (Phila) 1998;82:2275–2281.PubMedGoogle Scholar
  40. 41.
    Richard P, Amador Del Valle G, Moreau P, et al. Viridans streptococcal bacteraemia in patients with neutropenia. Lancet 1995;345:1607–1609.PubMedGoogle Scholar
  41. 42.
    Bostrom B, Weisdorf D. Mucositis and alpha-streptococcal sepsis in bone marrow transplant recipients. Lancet 1984;1:1120–1121.PubMedGoogle Scholar
  42. 43.
    Ringden O, Heimdahl A, Lonnqvist B, Malmborg AS, Wilczek H. Decreased incidence of viridans streptococcal septicaemia in allogeneic bone marrow transplant recipients after the introduction of acyclovir. Lancet 1984;1:744.PubMedGoogle Scholar
  43. 44.
    Bochud PY, Eggiman P, Calandra T, Van Melle G, Saghafi L, Francioli P. Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis 1994;18:25–31.PubMedGoogle Scholar
  44. 45.
    Shenep JL. Viridans-group streptococcal infections in immunocompromised hosts. Int J Antimicrob Agents 2000;14:129–135.PubMedGoogle Scholar
  45. 46.
    Marron A, Carratala J, Alcaide F, Fernandez-Sevilla A, Gudiol F. High rates of resistance to cephalosporins among viridans-group streptococci causing bacteremia in neutropenic cancer patients. J Antimicrob Chemother 2001;47:87–91.PubMedGoogle Scholar
  46. 47.
    Lyytikainen O, Rautio M, Carlson P, et al. Nosocomial bloodstream infections due to viridans streptococci in haematological and non-haematological patients: species distribution and antimicrobial resistance. J Antimicrob Chemother 2004;53:631–634.PubMedGoogle Scholar
  47. 48.
    Maki DG, Agger WA. Enterococcal bacteremia: clinical features, the risk of endocarditis, and management. Medicine (Baltim) 1988;67:248–269.PubMedGoogle Scholar
  48. 49.
    Anonymous. National Nosocomial Infections Surveillance (NNIS) System Report. Data summary from January 1992 through June 2003, issued August 2003. Am J Infect Control 2003;31:481–498.Google Scholar
  49. 50.
    Lautenbach E, Bilker WB, Brennan PJ. Enterococcal bacteremia: risk factors for vancomycin resistance and predictors of mortality. Infect Control Hosp Epidemiol 1999;20:318–323.PubMedGoogle Scholar
  50. 51.
    Chanock SJ, Pizzo PA. Fever in the neutropenic host. Infect Dis Clin N Am 1996;10:777–796.Google Scholar
  51. 52.
    Rolston KV, Bodey GP. Diagnosis and management of perianal and perirectal infection in the granulocytopenic patient. Curr Clin Top Infect Dis 1993;13:164–171.PubMedGoogle Scholar
  52. 53.
    Lopez FA, Sanders CV. Dermatologic infections in the immunocompromised (non-HIV) host. Infect Dis Clin N Am 2001;15:671–702, xi.Google Scholar
  53. 54.
    File TM. Necrotizing soft tissue infections. Curr Infect Dis Rep 2003;5:407–415.PubMedGoogle Scholar
  54. 55.
    Stamenkovic I, Lew PD. Early recognition of potentially fatal necrotizing fasciitis. The use of frozen-section biopsy. N Engl J Med 1984;310:1689–1693.PubMedGoogle Scholar
  55. 56.
    Bodey GP. Unusual presentations of infection in neutropenic patients. Int J Antimicrob Agents 2000;16:93–95.PubMedGoogle Scholar
  56. 57.
    Johnson S, Driks MR, Tweten RK, et al. Clinical courses of seven survivors of Clostridium septicum infection and their immunologic responses to alpha toxin. Clin Infect Dis 1994;19:761–764.PubMedGoogle Scholar
  57. 58.
    Horton KM, Corl FM, Fishman EK. CT evaluation of the colon: inflammatory disease. Radiographics 2000;20:399–418.PubMedGoogle Scholar
  58. 59.
    Schlatter M, Snyder K, Freyer D. Successful nonoperative management of typhlitis in pediatric oncology patients. J Pediatr Surg 2002;37:1151–1155.PubMedGoogle Scholar
  59. 60.
    Rolston KV. The spectrum of pulmonary infections in cancer patients. Curr Opin Oncol 2001;13:218–223.PubMedGoogle Scholar
  60. 61.
    Okamoto Y, Ribeiro RC, Srivastava DK, Shenep JL, Pui CH, Razzouk BI. Viridans streptococcal sepsis: clinical features and complications in childhood acute myeloid leukemia. J Pediatr Hematol Oncol 2003;25:696–703.PubMedGoogle Scholar
  61. 62.
    Maschmeyer G. Pneumonia in febrile neutropenic patients: radiologic diagnosis. Curr Opin Oncol 2001;13:229–235.PubMedGoogle Scholar
  62. 63.
    Rano A, Agusti C, Jimenez P, et al. Pulmonary infiltrates in non-HIV immunocompromised patients: a diagnostic approach using non-invasive and bronchoscopic procedures. Thorax 2001;56:379–387.PubMedGoogle Scholar
  63. 64.
    Ninane V. Bronchoscopic invasive diagnostic techniques in the cancer patient. Curr Opin Oncol 2001;13:236–241.PubMedGoogle Scholar
  64. 65.
    Maschmeyer G, Link H, Hiddemann W, Meyer P, Helmerking M, Adam D. Interventional antimicrobial strategy in febrile neutropenic patients. Results of a multicenter study in 1,260 patients with hematological malignancies. The Interventional Antimicrobial Strategy Study Group, Paul Ehrlich Society for Chemotherapy. Onkologie 1990;13:38–42.PubMedGoogle Scholar
  65. 66.
    Kyne L, Farrell RJ, Kelly CP. Clostridium difficile. Gastroenterol Clin N Am 2001;30:753–777, ix–x.Google Scholar
  66. 67.
    Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002;34:346–353.PubMedGoogle Scholar
  67. 68.
    Archibald LK, Banerjee SN, Jarvis WR. Secular trends in hospital-acquired Clostridium difficile disease in the United States, 1987–2001. J Infect Dis 2004;189:1585–1589.PubMedGoogle Scholar
  68. 69.
    Pituch H, van Belkum A, van den Braak N, et al. Clindamycin-resistant, toxin A-negative, toxin B-positive Clostridium difficile strains cause antibiotic-associated diarrhea among children hospitalized in a hematology unit. Clin Microbiol Infect 2003;9:903–904.PubMedGoogle Scholar
  69. 70.
    Blot E, Escande MC, Besson D, et al. Outbreak of Clostridium difficile-related diarrhoea in an adult oncology unit: risk factors and microbiological characteristics. J Hosp Infect 2003;53:187–192.PubMedGoogle Scholar
  70. 71.
    Hornbuckle K, Chak A, Lazarus HM, et al. Determination and validation of a predictive model for Clostridium difficile diarrhea in hospitalized oncology patients. Ann Oncol 1998;9:307–311.PubMedGoogle Scholar
  71. 72.
    Komatsu M, Kato H, Aihara M, et al. High frequency of antibiotic-associated diarrhea due to toxin A-negative, toxin B-positive Clostridium difficile in a hospital in Japan and risk factors for infection. Eur J Clin Microbiol Infect Dis 2003;22:525–529.PubMedGoogle Scholar
  72. 73.
    Bartlett JG. Clostridium difficile infection: pathophysiology and diagnosis. Semin Gastrointest Dis 1997;8:12–21.PubMedGoogle Scholar
  73. 74.
    Bartlett JG. Antimicrobial agents implicated in Clostridium difficile toxin-associated diarrhea of colitis. Johns Hopkins Med J 1981;149:6–9.PubMedGoogle Scholar
  74. 75.
    Delmee M. Laboratory diagnosis of Clostridium difficile disease. Clin Microbiol Infect 2001;7:411–416.PubMedGoogle Scholar
  75. 76.
    Kawamoto S, Horton KM, Fishman EK. Pseudomembranous colitis: spectrum of imaging findings with clinical and pathologic correlation. Radiographics 1999;19:887–897.PubMedGoogle Scholar
  76. 77.
    Bartlett JG. Management of Clostridium difficile infection and other antibiotic-associated diarrhoeas. Eur J Gastroenterol Hepatol 1996;8:1054–1061.PubMedGoogle Scholar
  77. 78.
    Apisarnthanarak A, Razavi B, Mundy LM. Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature. Clin Infect Dis 2002;35:690–696.PubMedGoogle Scholar
  78. 79.
    Mayfield JL, Leet T, Miller J, Mundy LM. Environmental control to reduce transmission of Clostridium difficile. Clin Infect Dis 2000;31:995–1000.PubMedGoogle Scholar
  79. 80.
    Simor AE, Bradley SF, Strausbaugh LJ, Crossley K, Nicolle LE. Clostridium difficile in long-term-care facilities for the elderly. Infect Control Hosp Epidemiol 2002;23:696–703.PubMedGoogle Scholar
  80. 81.
    Crnich CJ, Maki DG. The role of intravascular devices in sepsis. Current Infect Dis Rep 2001;3:497–506.Google Scholar
  81. 82.
    Pittet D, Tarara D, Wenzel R. Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1994;271:1598–1601.PubMedGoogle Scholar
  82. 83.
    Rello J, Ochagavia A, Sabanes E, et al. Evaluation of outcome of intravenous catheter-related infections in critically ill patients. Am J Respir Crit Care Med 2000;162:1027–1030.PubMedGoogle Scholar
  83. 84.
    Kluger D, Maki D. The relative risk of intravascular device-related bloodstream infections with different types of intravascular devices in adults. A meta-analysis of 206 published studies [abstract]. Infect Control Hosp Epidemiol 2000;21:95–96.Google Scholar
  84. 85.
    Maki DG, Crnich CJ. Line sepsis in the ICU. Semin Respir Crit Care Med 2002;24:22–36.Google Scholar
  85. 86.
    O’Grady NP, Barie PS, Bartlett JG, et al. Practice guidelines for evaluating new fever in critically ill adult patients. Task Force of the Society of Critical Care Medicine and the Infectious Diseases Society of America. Clin Infect Dis 1998;26:1042–1059.PubMedGoogle Scholar
  86. 87.
    Safdar N, Maki DG. Inflammation at the insertion site is not predictive of catheter-related bloodstream infection with short-term, noncuffed central venous catheters [comment]. Crit Care Med 2002;30:2632–2635.PubMedGoogle Scholar
  87. 88.
    Mermel LA, Maki DG. Detection of bacteremia in adults: consequences of culturing an inadequate volume of blood. Ann Intern Med 1993;119:270–272.PubMedGoogle Scholar
  88. 89.
    Gaur AH, Giannini MA, Flynn PM, et al. Optimizing blood culture practices in pediatric immunocompromised patients: evaluation of media types and blood culture volume. Pediatr Infect Dis J 2003;22:545–552.PubMedGoogle Scholar
  89. 90.
    Beutz M, Sherman G, Mayfield J, Fraser VJ, Kollef MH. Clinical utility of blood cultures drawn from central vein catheters and peripheral venipuncture in critically ill medical patients. Chest 2003;123:854–861.PubMedGoogle Scholar
  90. 91.
    Tacconelli E, Tumbarello M, Pittiruti M, et al. Central venous catheter-related sepsis in a cohort of 366 hospitalised patients. Eur J Clin Microbiol Infect Dis 1997;16:203–209.PubMedGoogle Scholar
  91. 92.
    Gowardman JR, Montgomery C, Thirlwell S, et al. Central venous catheter-related bloodstream infections: an analysis of incidence and risk factors in a cohort of 400 patients. Intens Care Med 1998;24:1034–1039.Google Scholar
  92. 93.
    Bouza E, Burillo A, Munoz P. Catheter-related infections: diagnosis and intravascular treatment. Clin Microbiol Infect 2002;8:265–274.PubMedGoogle Scholar
  93. 94.
    Raad I, Hanna HA, Alakech B, Chatzinikolaou I, Johnson MM, Tarrand J. Differential time to positivity: a useful method for diagnosing catheter-related bloodstream infections. Ann Intern Med 2003;140:18–25.Google Scholar
  94. 95.
    Moonens F, el Alami S, Van Gossum A, Struelens MJ, Serruys E. Usefulness of gram staining of blood collected from total parenteral nutrition catheter for rapid diagnosis of catheter-related sepsis. J Clin Microbiol 1994;32:1578–1579.PubMedGoogle Scholar
  95. 96.
    Kite P, Dobbins BM, Wilcox MH, McMahon MJ. Rapid diagnosis of central-venous-catheter-related bloodstream infection without catheter removal. Lancet 1999;354:1504–1507.PubMedGoogle Scholar
  96. 97.
    Verghese A, Widrich WC, Arbeit RD. Central venous septic thrombophlebitis: the role of medical therapy. Medicine (Baltim) 1985;64:394–400.PubMedGoogle Scholar
  97. 98.
    Martinez E, Mensa J, Rovira M, et al. Central venous catheter exchange by guidewire for treatment of catheter-related bacteraemia in patients undergoing BMT or intensive chemotherapy. Bone Marrow Transplantat 1999;23:41–44.Google Scholar
  98. 99.
    Maki DG. Managment of life-threatening infection in the intensive care unit. In: Prough DS (ed) Critical Care Medicine: Preoperative Management, 2nd ed. Philadelphia: Lippincott Williams & Williams, 2002:616–648.Google Scholar
  99. 100.
    Malanoski GJ, Samore MH, Pefanis A, Karchmer AW. Staphylococcus aureus catheter-associated bacteremia. Minimal effective therapy and unusual infectious complications associated with arterial sheath catheters. Arch Intern Med 1995;155:1161–1166.PubMedGoogle Scholar
  100. 101.
    Fowler VG Jr, Li J, Corey GR, et al. Role of echocardiography in evaluation of patients with Staphylococcus aureus bacteremia: experience in 103 patients. J Am Coll Cardiol 1997;30:1072–1078.PubMedGoogle Scholar
  101. 102.
    Nguyen MH, Peacock JE Jr, Tanner DC, et al. Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Arch Intern Med 1995;155:2429–2435.PubMedGoogle Scholar
  102. 103.
    Rex JH, Bennett JE, Sugar AM, et al. Intravascular catheter exchange and duration of candidemia. Clin Infect Dis 1995;21:994–996.PubMedGoogle Scholar
  103. 104.
    Anaissie EJ, Rex JH, Uzun O, Vartivarian S. Predictors of adverse outcome in cancer patients with candidemia. Am J Med 1998;104:238–245.PubMedGoogle Scholar
  104. 105.
    Messing B, Man F, Colimon R, Thuillier F, Beliah M. Antibiotic lock technique is an effective treatment of bacterial catheter-related sepsis during parenteral nutrition. Clin Nutr 1990;9:220–224.PubMedGoogle Scholar
  105. 106.
    Cuntz D, Michaud L, Guimber D, Husson MO, Gottrand F, Turck D. Local antibiotic lock for the treatment of infections related to central catheters in parenteral nutrition in children. JPEN (J Parenter Enteral Nutr) 2002;26:104–108.Google Scholar
  106. 107.
    Guedon C, Nouvellon M, Lalaude O, Lerebours E. Efficacy of antibiotic-lock technique with teicoplanin in Staphylococcus epidermidis catheter-related sepsis during long-term parenteral nutrition. J JPEN (J Parenter Enteral Nutr) 2002;26:109–113.Google Scholar
  107. 108.
    Brothers TE, Von Moll LK, Niederhuber JE, Roberts JA, Walker-Andrews S, Ensminger WD. Experience with subcutaneous infusion ports in three hundred patients. Surg Gynecol Obstet 1988;166:295–301.PubMedGoogle Scholar
  108. 109.
    Domingo P, Fontanet A, Sanchez F, Allende L, Vazquez G. Morbidity associated with long-term use of totally implantable ports in patients with AIDS. Clin Infect Dis 1999;29:346–351.PubMedGoogle Scholar
  109. 110.
    Longuet P, Douard MC, Maslo C, Benoit C, Arlet G, Leport C. Limited efficacy of antibiotic lock techniques (ALT) in catheter related bacteremia of totally implanted ports (TIP) in HIV infected oncologic patients [abstract]. Abstracts and Proceedings from the 35th Interscience Conference of Antimicrobial Agents and Chemotherapy. Washington, DC: ASM Press, 1995:J5.Google Scholar
  110. 111.
    Crnich CJ, Maki DG. Infections of vascular devices. In: Cohen J (ed) Infectious Diseases, 2nd ed. Philadelphia: Mosby, 2003:722–743.Google Scholar
  111. 112.
    Raad I, Davis S, Khan A, Tarrand J, Elting L, Bodey GP. Impact of central venous catheter removal on the recurrence of catheter-related coagulase-negative staphylococcal bacteremia. Infect Control Hosp Epidemiol 1992;13:215–221.PubMedGoogle Scholar
  112. 113.
    Mermel LA, Farr BM, Sherertz RJ, et al. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 2001;32:1249–1272.PubMedGoogle Scholar
  113. 114.
    Raad, II, Sabbagh MF. Optimal duration of therapy for catheter-related Staphylococcus aureus bacteremia: a study of 55 cases and review. Clin Infect Dis 1992;14:75–82.PubMedGoogle Scholar
  114. 115.
    Rosen AB, Fowler VG, Jr., Corey GR, et al. Cost-effectiveness of transesophageal echocardiography to determine the duration of therapy for intravascular catheter-associated Staphylococcus aureus bacteremia. Ann Intern Med 1999;130:810–820.PubMedGoogle Scholar
  115. 116.
    O’Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis 2002;35:1281–1307.Google Scholar
  116. 117.
    Crnich CJ, Maki DG. The promise of novel technology for the prevention of intravascular device-related bloodstream infection. II. Long-term devices. Clin Infect Dis 2002;34:1362–1368.PubMedGoogle Scholar
  117. 118.
    Henrickson KJ, Axtell RA, Hoover SM, et al. Prevention of central venous catheter-related infections and thrombotic events in immunocompromised children by the use of vancomycin/ciprofloxacin/heparin flush solution: a randomized, multicenter, double-blind trial. J Clin Oncol 2000;18:1269–1278.PubMedGoogle Scholar
  118. 119.
    Kuypers DR, Evenepoel P, Maes BD, Coosemans W, Pirenne J, Vanrenterghem YF. Role of immunosuppressive drugs in the development of tissue-invasive cytomegalovirus infection in renal transplant recipients. Transplant Proc 2002;34:1164–1170.PubMedGoogle Scholar
  119. 120.
    Rasoul-Rockenschaub S, Zielinski CC, Muller C, Tichatschek E, Popow-Kraupp T, Kunz C. Viral reactivation as a cause of unexplained fever in patients with progressive metastatic breast cancer. Cancer Immunol Immunother 1990;31:191–195.PubMedGoogle Scholar
  120. 121.
    Perkins JG, Flynn JM, Howard RS, Byrd JC. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer (Phila) 2002;94:2033–2039.PubMedGoogle Scholar
  121. 122.
    Perez-Simon JA, Kottaridis PD, Martino R, et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 2002;100:3121–3127.PubMedGoogle Scholar
  122. 123.
    Reusser P. Opportunistic viral infections. In: Powderly WG (ed) Infectious Diseases, vol 1. New York: Mosby, 2003:1169–1181.Google Scholar
  123. 124.
    Dykewicz CA. Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients. Clin Infect Dis 2001;33:139–144.PubMedGoogle Scholar
  124. 125.
    Mitchell PS, Espy MJ, Smith TF, et al. Laboratory diagnosis of central nervous system infections with herpes simplex virus by PCR performed with cerebrospinal fluid specimens. J Clin Microbiol 1997;35:2873–2877.PubMedGoogle Scholar
  125. 126.
    Schloss L, van Loon AM, Cinque P, et al. An international external quality assessment of nucleic acid amplification of herpes simplex virus. J Clin Virol 2003;28:175–185.PubMedGoogle Scholar
  126. 127.
    Gnann JW. Varicella-zoster virus: atypical presentations and unusual complications. J Infect Dis 2002;186:S91–S98.PubMedGoogle Scholar
  127. 128.
    Feldman S, Lott L. Varicella in children with cancer. Impact of antiviral therapy and prophylaxis. Pediatrics 1987;80:465–472.PubMedGoogle Scholar
  128. 129.
    Wood MJ. Viral infections in neutropenia: current problems and chemotherapeutic control. J Antimicrob Chemother 1998;41:81–93.PubMedGoogle Scholar
  129. 130.
    Cohen JI, Brunell PA, Straus SE, Krause PR. Recent advances in varicella-zoster virus infection. Ann Intern Med 1999;130:922–932.PubMedGoogle Scholar
  130. 131.
    Saito S, Yano T, Koga H, Arikawa K, Koyanagi N, Oizumi K. Case of varicella-zoster pneumonia with bronchioalveolar lavage confirmed by the detection of VZV DNA in the bronchial washing by the polymerase chain reaction. Kansenshogaku Zasshi (J the Japanese Association for Infectious Diseases) 1999;73:346–350.Google Scholar
  131. 132.
    Kleinschmidt-DeMasters BK, Gilden DH. Varicella-Zoster virus infections of the nervous system: clinical and pathologic correlates. Arch Pathol Lab Med 2001;125:770–780.PubMedGoogle Scholar
  132. 133.
    Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). (MMWR Morb Mortal Wkly Rep) 1996;45:1–25.Google Scholar
  133. 134.
    Prevention of varicella. Updated recommendations of the Advisory Committee on Immunizations Practices (ACIP). MMWR (Morb Mortal Wkly Rep) 1999;48:1–5.Google Scholar
  134. 135.
    Patel R, Paya CV. Infections in solid-organ transplant recipients. Clin Microbiol Rev 1997;10:86–124.PubMedGoogle Scholar
  135. 136.
    Konoplev S, Champlin RE, Giralt S, et al. Cytomegalovirus pneumonia in adult autologous blood and marrow transplant recipients. Bone Marrow Transplant 2001;27:877–881.PubMedGoogle Scholar
  136. 137.
    Nguyen Q, Estey E, Raad I, et al. Cytomegalovirus pneumonia in adults with leukemia: an emerging problem. Clin Infect Dis 2001;32:539–545.PubMedGoogle Scholar
  137. 138.
    Meyers JD, Ljungman P, Fisher LD. Cytomegalovirus excretion as a predictor of cytomegalovirus disease after marrow transplantation: importance of cytomegalovirus viremia. J Infect Dis 1990;162:373–380.PubMedGoogle Scholar
  138. 139.
    Enright H, Haake R, Weisdorf D, et al. Cytomegalovirus pneumonia after bone marrow transplantation. Risk factors and response to therapy. Transplantation 1993;55:1339–1346.PubMedGoogle Scholar
  139. 140.
    Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 193;118:173–178.Google Scholar
  140. 141.
    Boeckh M, Boivin G. Quantitation of cytomegalovirus: methodologic aspects and clinical applications. Clin Microbiol 1998;11:533–554.Google Scholar
  141. 142.
    Cortez KJ, Fischer SH, Fahle GA, et al. Clinical trial of quantitative real-time polymerase chain reaction for detection of cytomegalovirus in peripheral blood of allogeneic hematopoietic stem-cell transplant recipients. J Infect Dis 2003;188:967–972.PubMedGoogle Scholar
  142. 143.
    Reed EC, Bowden RA, Dandliker PS, Lilleby KE, Meyers JD. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med 1988;109:783–788.PubMedGoogle Scholar
  143. 144.
    Machado CM, Dulley FL, Boas LS, et al. CMV pneumonia in allogeneic BMT recipients undergoing early treatment of pre-emptive ganciclovir therapy. Bone Marrow Transplant 2000;26:413–417.PubMedGoogle Scholar
  144. 145.
    Goodrich JM, Mori M, Gleaves CA, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 1991;325:1601–1607.PubMedGoogle Scholar
  145. 146.
    Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman SJ, Zaia JA. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. The City of Hope-Stanford-Syntex CMV Study Group [comment]. N Engl J Med 1991;324:1005–1011.PubMedGoogle Scholar
  146. 147.
    Singhal S, Powles R, Treleaven J, et al. Cytomegaloviremia after autografting for leukemia: clinical significance and lack of effect on engraftment. Leukemia 1997;117:835–838.Google Scholar
  147. 148.
    Baker KS, DeFor TE, Burns LJ, Ramsay NK, Neglia JP, Robison LL. New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors [erratum appears in J Clin Oncol 2003;21(16):3181]. J Clin Oncol 2003;21:1352–1358.PubMedGoogle Scholar
  148. 149.
    Loren AW, Porter DL, Stadtmauer EA, Tsai DE. Post-transplant lymphoproliferative disorder: a review. Bone Marrow Transplant 2003;31:145–155.PubMedGoogle Scholar
  149. 150.
    Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000;343:481–492.PubMedGoogle Scholar
  150. 151.
    Singh N, Paterson DL. Encephalitis caused by human herpesvirus-6 in transplant recipients: relevance of a novel neurotropic virus. Transplantation 2000;69:2474–2479.PubMedGoogle Scholar
  151. 152.
    Cole PD, Stiles J, Boulad F, et al. Successful treatment of human herpesvirus 6 encephalitis in a bone marrow transplant recipient. Clin Infect Dis 1998;27:653–654.PubMedGoogle Scholar
  152. 153.
    Couch RB, Englund JA, Whimbey E. Respiratory viral infections in immunocompetent and immunocompromised persons. Am J Med 1997;102:2–9; discussion 25–26.PubMedGoogle Scholar
  153. 154.
    Englund JA, Anderson LJ, Rhame FS. Nosocomial transmission of respiratory syncytial virus in immunocompromised adults. J Clin Microbiol 1991;29:115–119.PubMedGoogle Scholar
  154. 155.
    Whimbey E, Champlin RE, Couch RB, et al. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis 1996;22:778–782.PubMedGoogle Scholar
  155. 156.
    Whimbey E, Couch RB, Englund JA, et al. Respiratory syncytial virus pneumonia in hospitalized adult patients with leukemia. Clin Infect Dis 1995;21:376–379.PubMedGoogle Scholar
  156. 157.
    Hindiyeh M, Hillyard DR, Carroll KC. Evaluation of the Prodesse Hexaplex multiplex PCR assay for direct detection of seven respiratory viruses in clinical specimens. Am J Clin Pathol 2001;116:218–224.PubMedGoogle Scholar
  157. 158.
    Ison MG, Hayden FG. Viral infections in immunocompromised patients: what’s new with respiratory viruses? Curr Opin Infect Dis 2002;15:355–367.PubMedGoogle Scholar
  158. 159.
    Nichols WG, Gooley T, Boeckh M. Community-acquired respiratory syncytial virus and parainfluenza virus infections after hematopoietic stem cell transplantation: the Fred Hutchinson Cancer Research Center experience. Biol Blood Marrow Transplant 2001;7:11S–15S.PubMedGoogle Scholar
  159. 160.
    Salgado CD, Farr BM, Hall KK, Hayden FG. Influenza in the acute hospital setting. Lancet Infect Dis 2002;2:145–155.PubMedGoogle Scholar
  160. 161.
    Hall CB. Nosocomial respiratory syncytial virus infections: the “Cold War” has not ended. Clin Infect Dis 2000;31:590–596.PubMedGoogle Scholar
  161. 162.
    Bridges CB, Harper SA, Fukuda K, et al. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep Recommend Rep 2003;52:1–34; quiz CE31–CE34.Google Scholar
  162. 163.
    Wheat LJ, Goldman M, Sarosi GA. Fungal infections in the immunocompromised host. In: Young LS (ed) Clinical Approach to Infection in the Compromised Host, 4th ed. New York: Kluwer/Plenum, 2002:215–247.Google Scholar
  163. 164.
    Colombo AL, Perfect J, DiNubile M, et al. Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis 2003;22:470–474.PubMedGoogle Scholar
  164. 165.
    Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis 2000;30:662–678.PubMedGoogle Scholar
  165. 166.
    National Nosocomial Infections Surveillance (NNIS) System Report. Data summary from January 1992 to June 2002, issued August 2002. AJIC Am J Infect Control 2002;30:2002:458–475.Google Scholar
  166. 167.
    Pittet D, Li N, Woolson R, Wenzel R. Microbiological factors influencing the outcome of nosocomial bloodstream infections: a 6-year validated, population-based model. Clin Infect Dis 1997;24:1068–1078.PubMedGoogle Scholar
  167. 168.
    Viscoli C, Girmenia C, Marinus A, et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999;28:1071–1079.PubMedGoogle Scholar
  168. 169.
    Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Risk factors for hospital-acquired candidemia. A matched case-control study. Arch Intern Med 1989;149:2349–2353.PubMedGoogle Scholar
  169. 170.
    Walsh TJ, Rex JH. All catheter-related candidemia is not the same: assessment of the balance between the risks and benefits of removal of vascular catheters. Clin Infect Dis 2002;34:600–602.PubMedGoogle Scholar
  170. 171.
    Hockey LJ, Fujita NK, Gibson TR, Rotrosen D, Montgomerie JZ, Edwards JE Jr. Detection of fungemia obscured by concomitant bacteremia: in vitro and in vivo studies. J Clin Microbiol 1982;16:1080–1085.PubMedGoogle Scholar
  171. 172.
    Munoz P, Bernaldo de Quiros JC, Berenguer J, Rodriguez Creixems M, Picazo JJ, Bouza E. Impact of the BACTEC NR system in detecting Candida fungemia. J Clin Microbiol 1990;28:639–641.PubMedGoogle Scholar
  172. 173.
    Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004;38:161–189.PubMedGoogle Scholar
  173. 174.
    Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994;331:1325–1330.PubMedGoogle Scholar
  174. 175.
    Phillips P, Shafran S, Garber G, et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Eur J Clin Microbiol Infect Dis 1997;16:337–345.PubMedGoogle Scholar
  175. 176.
    Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347:2020–2029.PubMedGoogle Scholar
  176. 177.
    Thaler M, Pastakia B, Shawker TH, O’Leary T, Pizzo PA. Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. Ann Intern Med 1988;108:88–100.PubMedGoogle Scholar
  177. 178.
    Denning DW. Invasive aspergillosis. Clin Infect Dis 1998;26:781–805.PubMedGoogle Scholar
  178. 179.
    Baddley JW, Stroud TP, Salzman D, Pappas PG. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001;32:1319–1324.PubMedGoogle Scholar
  179. 180.
    Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 202;100:4358–4366.Google Scholar
  180. 181.
    Allo MD, Miller J, Townsend T, Tan C. Primary cutaneous aspergillosis associated with Hickman intravenous catheters. N Engl J Med 1987;317:1105–1108.PubMedGoogle Scholar
  181. 182.
    Warris A, Gaustad P, Meis JF, Voss A, Verweij PE, Abrahamsen TG. Recovery of filamentous fungi from water in a paediatric bone marrow transplantation unit. J Hosp Infect 2001;47:143–148.PubMedGoogle Scholar
  182. 183.
    Denning DW. Therapeutic outcomes in invasive aspergillosis. Clin Infect Dis 1996;23:608–615.PubMedGoogle Scholar
  183. 184.
    Denning DW, Marinus A, Cohen J, et al. An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. J Infect 1998;37:173–180.PubMedGoogle Scholar
  184. 185.
    Kuhlman JE, Fishman EK, Siegelman SS. Invasive pulmonary aspergillosis in acute leukemia: characteristic findings on CT, the CT halo sign, and the role of CT in early diagnosis. Radiology 1985;157:611–614.PubMedGoogle Scholar
  185. 186.
    Curtis AM, Smith GJ, Ravin CE. Air crescent sign of invasive aspergillosis. Radiology 1979;133:17–21.PubMedGoogle Scholar
  186. 187.
    Perfect JR, Cox GM, Lee JY, et al. The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clin Infect Dis 2001;33:1824–1833.PubMedGoogle Scholar
  187. 188.
    Maetens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001;97:1604–1610.Google Scholar
  188. 189.
    Denning DW. Echinocandins: a new class of antifungal. J Antimicrob Chemother 2002;49:889–891.PubMedGoogle Scholar
  189. 190.
    Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis: a disease spectrum, treatment practices, and outcomes. Medicine (Baltim) 2000;79:250–260.PubMedGoogle Scholar
  190. 191.
    Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408–415.PubMedGoogle Scholar
  191. 192.
    Manavathu EK, Alangaden GJ, Chandrasekar PH. Differential activity of triazoles in two-drug combinations with the echinocandin caspofungin against Aspergillus fumigatus. J Antimicrob Chemother 2003;51:1423–1425.PubMedGoogle Scholar
  192. 193.
    Dannaoui E, Lortholary O, Dromer F. In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus. Antimicrob Agents Chemother 2004;48:970–978.PubMedGoogle Scholar
  193. 194.
    Segal BH, Walsh TJ. Opportunistic fungal infections. In: Powderly WG (ed) Infectious Diseases, vol 1. New York: Mosby, 2003:1155–1167.Google Scholar
  194. 195.
    Leong KW, Crowley B, White B, et al. Cutaneous mucormycosis due to Absidia corymbifera occurring after bone marrow transplantation. Bone Marrow Transplant 1997;19:513–515.PubMedGoogle Scholar
  195. 196.
    Fleming RV, Walsh TJ, Anaissie EJ. Emerging and less common fungal pathogens. Infect Dis Clin N Am 2002;16:915–933, vi–vii.Google Scholar
  196. 197.
    Anaissie EJ, Penzak SR, Dignani MC. The hospital water supply as a source of nosocomial infections: a plea for action. Arch Intern Med 2002;162:1483–1492.PubMedGoogle Scholar
  197. 198.
    Raad I, Tarrand J, Hanna H, et al. Epidemiology, molecular mycology, and environmental sources of Fusarium infection in patients with cancer. Infect Control Hosp Epidemiol 2002;23:532–537.PubMedGoogle Scholar
  198. 199.
    Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years’ experience at a cancer center and implications for management. Blood 1997;90:999–1008.PubMedGoogle Scholar
  199. 200.
    Walsh TJ, Groll AH. Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century. Transplant Infect Dis 1999;1:247–261.Google Scholar
  200. 201.
    Sickles EA, Greene WH, Wiernik PH. Clinical presentation of infection in granulocytopenic patients. Arch Intern Med 1975;135:715–719.PubMedGoogle Scholar
  201. 202.
    Siegel DL, Edelstein PH, Nachamkin I. Inappropriate testing for diarrheal diseases in the hospital. JAMA 1990;263:979–982.PubMedGoogle Scholar
  202. 203.
    Furno P, Bucaneve G, Del Favero A. Monotherapy or aminogly-coside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis. Lancet Infect Dis 2002;2:231–242.PubMedGoogle Scholar
  203. 204.
    Paul M, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. BMJ 2003;326:1111.PubMedGoogle Scholar
  204. 205.
    Paul M, Soares-Weiser K, Grozinsky S, Leibovici L. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropaenia. Cochrane Database Syst Rev 2003:CD003038.Google Scholar
  205. 206.
    Smith CE, Tillman BS, Howell AW, Longfield RN, Jorgensen JH. Failure of ceftazidime-amikacin therapy for bacteremia and meningitis due to Klebsiella pneumoniae producing an extended-spectrum beta-lactamase. Antimicrob Agents Chemother 1990;34:1290–1293.PubMedGoogle Scholar
  206. 207.
    Fleischhack G, Hartmann C, Simon A, et al. Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer. J Antimicrob Chemother 2001;47:841–853.PubMedGoogle Scholar
  207. 208.
    Giamarellou H, Bassaris HP, Petrikkos G, et al. Monotherapy with intravenous followed by oral high-dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever. Antimicrob Agents Chemother 2000;44:3264–3271.PubMedGoogle Scholar
  208. 209.
    Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002;34:634–640.PubMedGoogle Scholar
  209. 210.
    Peacock JE, Herrington DA, Wade JC, et al. Ciprofloxacin plus piperacillin compared with tobramycin plus piperacillin as empirical therapy in febrile neutropenic patients. A randomized, double-blind trial. Ann Intern Med 2002;137:77–87.PubMedGoogle Scholar
  210. 211.
    Rubin M, Hathorn JW, Marshall D, Gress J, Steinberg SM, Pizzo PA. Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med 1988;108:30–35.PubMedGoogle Scholar
  211. 212.
    Cometta A, Kern WV, De Bock R, et al. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis 2003;37:382–389.PubMedGoogle Scholar
  212. 213.
    Maki DG. Management of life-threatening infection in the intensive care unit. In: Murray MJ, Coursin DB (eds) Critical Care Medicine: Preoperative Management. Philadelphia: Lippincott, Williams & Wilkins, 2002.Google Scholar
  213. 214.
    Rybak MJ. Therapeutic options for gram-positive infections. J Hosp Infect 2001;49(suppl A):S25–S32.PubMedGoogle Scholar
  214. 215.
    Hughes WT, Armstrong D, Bodey GP, et al. From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990;161:381–396.PubMedGoogle Scholar
  215. 216.
    Talcott JA, Finberg R, Mayer RJ, Goldman L. The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med 1988;148:2561–2568.PubMedGoogle Scholar
  216. 217.
    Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 1992;10:316–322.PubMedGoogle Scholar
  217. 218.
    Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000;18:3038–3051.PubMedGoogle Scholar
  218. 219.
    DeGregorio MW, Lee WM, Linker CA, Jacobs RA, Ries CA. Fungal infections in patients with acute leukemia. Am J Med 1982;73:543–548.PubMedGoogle Scholar
  219. 220.
    Davies SV, Murray JA. Amphotericin and abolition of fever in neutropenic sepsis. Br Med J 1989;299:1339–1340.Google Scholar
  220. 221.
    Pizzo PA, Ribichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982;72:101–111.PubMedGoogle Scholar
  221. 222.
    Stein RS, Kayser J, Flexner JM. Clinical value of empirical amphotericin B in patients with acute myelogenous leukemia. Cancer (Phila) 1982;50:2247–2251.PubMedGoogle Scholar
  222. 223.
    Subira M, Martino R, Gomez L, Marti JM, Estany C, Sierra J. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies: a randomized, controlled trial. Eur J Haematol 2004;72:342–347.PubMedGoogle Scholar
  223. 224.
    Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999;340:764–771.PubMedGoogle Scholar
  224. 225.
    Wingard JR, White MH, Anaissie E, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group [comment]. Clin Infect Dis 2000;31:1155–1163.PubMedGoogle Scholar
  225. 226.
    Winston DJ, Hathorn JW, Schuster MG, et al. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med 2000;108:282–289.PubMedGoogle Scholar
  226. 227.
    Boogaerts M, Winston DJ, Bow EJ, et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 2001;135:412–422.PubMedGoogle Scholar
  227. 228.
    Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;346:225–234.PubMedGoogle Scholar
  228. 229.
    Powers JH, Dixon CA, Goldberger MJ. Voriconazole versus liposomal amphotericin B in patients with neutropenia and persistent fever. N Engl J Med 2002;346:289–290.PubMedGoogle Scholar
  229. 230.
    Aquino VM, Tkaczewski I, Buchanan GR. Early discharge of low-risk febrile neutropenic children and adolescents with cancer. Clin Infect Dis 1997;25:74–78.PubMedGoogle Scholar
  230. 231.
    Joshi JH, Schimpff SC, Tenney JH, Newman KA, de Jongh CA. Can antibacterial therapy be discontinued in persistently febrile granulocytopenic cancer patients? Am J Med 1984;76:450–457.PubMedGoogle Scholar
  231. 232.
    Talbot GH, Provencher M, Cassileth PA. Persistent fever after recovery from granulocytopenia in acute leukemia. Arch Intern Med 1988;148:129–135.PubMedGoogle Scholar
  232. 233.
    Flynn PM, Shenep JL, Crawford R, Hughes WT. Use of abdominal computed tomography for identifying disseminated fungal infection in pediatric cancer patients. Clin Infect Dis 1995;20:964–970.PubMedGoogle Scholar
  233. 234.
    Elting LS, Rubenstein EB, Rolston KV, Bodey GP. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 1997;25:247–259.PubMedGoogle Scholar
  234. 235.
    Clark OA, Lyman G, Castro AA, Clark LG, Djulbegovic B. Colony stimulating factors for chemotherapy induced febrile neutropenia. Cochrane Database Syst Rev 2003:CD003039.Google Scholar
  235. 236.
    Link H, Bohme A, Cornely OA, et al. Antimicrobial therapy of unexplained fever in neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol 2003;82(suppl 2):S105–S117.PubMedGoogle Scholar
  236. 237.
    Lucas KG. Another look at granulocyte transfusions in neutropenic patients with cancer. Infect Med 1996;13.Google Scholar
  237. 238.
    Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368–1377.PubMedGoogle Scholar
  238. 239.
    Connors AF Jr, Speroff T, Dawson NV, et al. The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT Investigators. JAMA 1996;276:889–897.PubMedGoogle Scholar
  239. 240.
    Sandham JD, Hull RD, Brant RF, et al. A randomized, controlled trial of the use of pulmonary-artery catheters in high-risk surgical patients. N Engl J Med 2003;348:5–14.PubMedGoogle Scholar
  240. 241.
    Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002;288:862–871.PubMedGoogle Scholar
  241. 242.
    Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699–709.PubMedGoogle Scholar
  242. 243.
    Shelton BK. Evidence-based care for the neutropenic patient with leukemia. Semin Oncol Nurs 2003;19:133–141.PubMedGoogle Scholar
  243. 244.
    Nauseef WM, Maki DG. A study of the value of simple protective isolation in patients with granulocytopenia. N Engl J Med 1981;304:448–453.PubMedGoogle Scholar
  244. 245.
    Boyce JM. Understanding and controlling methicillin-resistant Staphylococcus aureus infections. Infect Control Hosp Epidemiol 2001;23(9):485–487.Google Scholar
  245. 246.
    Wenzel RP, Reagan DR, Bertino JS Jr, Baron EJ, Arias K. Methicillin-resistant Staphylococcus aureus outbreak: a consensus panel’s definition and management guidelines. Am J Infect Control 1998;26:102–110.PubMedGoogle Scholar
  246. 247.
    Garner JS. Guideline for isolation precautions in hospitals. The Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1996;17:53–80.PubMedGoogle Scholar
  247. 248.
    Fridkin SK. Increasing prevalence of antimicrobial resistance in intensive care units. Crit Care Med 2001;29:N64–N68.PubMedGoogle Scholar
  248. 249.
    Warren DK, Fraser VJ. Infection control measures to limit antimicrobial resistance. Crit Care Med 2001;29:N128–N134.PubMedGoogle Scholar
  249. 250.
    Muto CA, Jernigan JA, Ostrowsky BE, et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect Control Hosp Epidemiol 2003;24:362–386.PubMedGoogle Scholar
  250. 251.
    Jernigan JA, Clemence MA, Stott GA, et al. Control of methicillin-resistant Staphylococcus aureus at a university hospital: one decade later. Infect Control Hospital Epidemiol 1995;16:686–696.Google Scholar
  251. 252.
    Farr BM. Hospital wards spreading vancomycin-resistant enterococci to intensive care units: returning coals to Newcastle. Crit Care Med 1998;26:1942–1943.PubMedGoogle Scholar
  252. 253.
    Walsh TJ, Vlahov D, Hansen SL, et al. Prospective microbiologic surveillance in control of nosocomial methicillin-resistant Staphylococcus aureus. Infect Control 1987;8:7–14.PubMedGoogle Scholar
  253. 254.
    Jernigan JA, Titus MG, Groschel DH, Getchell-White S, Farr BM. Effectiveness of contact isolation during a hospital outbreak of methicillin-resistant Staphylococcus aureus. Am J Epidemiol 1996;143:496–504.PubMedGoogle Scholar
  254. 255.
    Murray-Leisure KA, Geib S, Graceley D, et al. Control of epidemic methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol 1990;11:343–350.PubMedGoogle Scholar
  255. 256.
    Morris JG Jr, Shay DK, Hebden JN, et al. Enterococci resistant to multiple antimicrobial agents, including vancomycin. Establishment of endemicity in a university medical center. Ann Intern Med 1995;123:250–259.PubMedGoogle Scholar
  256. 257.
    Goetz AM, Rihs JD, Wagener MM, Muder RR. Infection and colonization with vancomycin-resistant Enterococcus faecium in an acute care Veterans Affairs Medical Center: a 2-year survey. Am J Infect Control 1998;26:558–562.PubMedGoogle Scholar
  257. 258.
    Ostrowsky BE, Trick WE, Sohn AH, et al. Control of vancomycin-resistant enterococcus in health care facilities in a region. N Engl J Med 2001;344:1427–1433.PubMedGoogle Scholar
  258. 259.
    Kotilainen P, Routamaa M, Peltonen R, et al. Eradication of methicillin-resistant Staphylococcus aureus from a health center ward and associated nursing home. Arch Intern Med 2001;161:859–863.PubMedGoogle Scholar
  259. 260.
    Zuckerman RA, Steele L, Venezia RA, Tobin EH. Undetected vancomycin-resistant Enterococcus in surgical intensive care unit patients. Infect Control Hosp Epidemiol 1999;20:685–686.PubMedGoogle Scholar
  260. 261.
    Maki DG, Zilz MA, McComick R. The effectiveness of using preemptive barrier precautions routinely (protective isolation) in all high-risk patients to prevent nosocomial infection with resistant organisms, especially MRSA, VRE and C. difficile. In: Thirty-fourth Annual Meeting of the Infectious Disease Society of North America, 1996, New Orleans, Louisiana.Google Scholar
  261. 262.
    van Voorhis J, Destefano L, Sobek S, et al. Impact of barrier precautions and cohorting on a monoclonal outbreak of vancomycin-resistant Enterococcus faecium (VRE). In: Society for Healthcare Epidemiology of America, 1997.Google Scholar
  262. 263.
    Klein BS, Perloff WH, Maki DG. Reduction of nosocomial infection during pediatric intensive care by protective isolation. N Engl J Med 1989;320:1714–1721.PubMedGoogle Scholar
  263. 264.
    Slota M, Green M, Farley A, Janosky J, Carcillo J. The role of gown and glove isolation and strict handwashing in the reduction of nosocomial infection in children with solid organ transplantation. Crit Care Med 2001;29:405–412.PubMedGoogle Scholar
  264. 265.
    Safdar N, Marx J, Meyer N, Maki DG. The effectiveness of preemptive enhanced barrier precautions for controlling MRSA in a burn unit. In: 43rd InterScience Conference on Antimicrobial Agents and Chemotherapy, 2003, Chicago, Illinois.Google Scholar
  265. 266.
    Srinivasan A, Song X, Ross T, Merz W, Brower R, Perl TM. A prospective study to determine whether cover gowns in addition to gloves decrease nosocomial transmission of vancomycin-resistant enterococci in an intensive care unit. Infect Control Hosp Epidemiol 2002;23:424–428.PubMedGoogle Scholar
  266. 267.
    Montecalvo MA, Jarvis WR, Uman J, et al. Infection-control measures reduce transmission of vancomycin-resistant enterococci in an endemic setting. Ann Intern Med 1999;131:269–272.PubMedGoogle Scholar
  267. 268.
    Koss WG, Khalili TM, Lemus JF, Chelly MM, Margulies DR, Shabot MM. Nosocomial pneumonia is not prevented by protective contact isolation in the surgical intensive care unit. Am Surg 2001;67.Google Scholar
  268. 269.
    Lew MA, Kehoe K, Ritz J, et al. Ciprofloxacin versus trimethoprim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: a randomized, controlled trial. J Clin Oncol 1995;13:239–250.PubMedGoogle Scholar
  269. 270.
    Prentice HG, Hann IM, Nazareth B, Paterson P, Bhamra A, Kibbler CC. Oral ciprofloxacin plus colistin: prophylaxis against bacterial infection in neutropenic patients. A strategy for the prevention of emergence of antimicrobial resistance. Br J Haematol 2001;115:46–52.PubMedGoogle Scholar
  270. 271.
    Cruciani M, Malena M, Bosco O, Nardi S, Serpelloni G, Mengoli C. Reappraisal with meta-analysis of the addition of grampositive prophylaxis to fluoroquinolone in neutropenic patients. J Clin Oncol 2003;21:4127–4137.PubMedGoogle Scholar
  271. 272.
    Bow EJ, Laverdiere M, Lussier N, Rotstein C, Cheang MS, Ioannou S. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta-analysis of randomized-controlled clinical trials. Cancer (Phila) 2002;94:3230–3246.PubMedGoogle Scholar
  272. 273.
    Kanda Y, Yamamoto R, Chizuka A, et al. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials. Cancer (Phila) 2000;89:1611–1625.PubMedGoogle Scholar
  273. 274.
    Wiederhold NP, Lewis RE, Kontoyiannis DP. Invasive aspergillosis in patients with hematologic malignancies. Pharmacotherapy 2003;23:1592–1610.PubMedGoogle Scholar
  274. 275.
    Fukuda T, Boeckh M, Carter RA, et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003;102:827–833.PubMedGoogle Scholar
  275. 276.
    Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326:845–851.PubMedGoogle Scholar
  276. 277.
    MacMillan ML, Goodman JL, DeFor TE, Weisdorf DJ. Fluconazole to prevent yeast infections in bone marrow transplantation patients: a randomized trial of high versus reduced dose, and determination of the value of maintenance therapy. Am J Med 2002;112:369–379.PubMedGoogle Scholar
  277. 278.
    Glasmacher A, Prentice A, Gorschluter M, et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a metaanalysis of 3,597 patients. J Clin Oncol 2003;21:4615–4626.PubMedGoogle Scholar
  278. 279.
    Mattiuzzi GN, Kantarjian H, Faderl S, et al. Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy. Cancer (Phila) 2004;100:581–589.PubMedGoogle Scholar
  279. 280.
    Bodey GP, Anaissie EJ, Elting LS, Estey E, O’Brien S, Kantarjian H. Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B. Cancer (Phila) 1994;73:2099–2106.PubMedGoogle Scholar
  280. 281.
    Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;346:225–234.PubMedGoogle Scholar
  281. 282.
    Cornely OA, Bohme A, Buchheidt D, et al. Prophylaxis of invasive fungal infections in patients with hematological malignancies and solid tumors: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003;82(suppl 2):S186–S200.PubMedGoogle Scholar
  282. 283.
    Kish MA. Guide to development of practice guidelines. Clin Infect Dis 2001;32:851–854.PubMedGoogle Scholar
  283. 284.
    Minotti V, Gentile G, Bucaneve G, et al. Domiciliary treatment of febrile episodes in cancer patients: a prospective randomized trial comparing oral versus parenteral empirical antibiotic treatment. Support Care Cancer 1999;7:134–139.PubMedGoogle Scholar
  284. 285.
    Paganini HR, Sarkis CM, De Martino MG, et al. Oral administration of cefixime to lower risk febrile neutropenic children with cancer. Cancer (Phila) 2000;88:2848–2852.PubMedGoogle Scholar
  285. 286.
    Paganini H, Rodriguez-Brieshcke T, Zubizarreta P, et al. Oral ciprofloxacin in the management of children with cancer with lower risk febrile neutropenia. Cancer (Phila) 2001;91:1563–1567.PubMedGoogle Scholar
  286. 287.
    Paganini H, Gomez S, Ruvinsky S, et al. Outpatient, sequential, parenteral-oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease: a single-center, randomized, controlled trial in Argentina. Cancer (Phila) 2003;97:1775–1780.PubMedGoogle Scholar
  287. 288.
    Shenep JL, Flynn PM, Baker DK, et al. Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer. Clin Infect Dis 2001;32:36–43.PubMedGoogle Scholar
  288. 289.
    Mullen CA, Petropoulos D, Roberts WM, et al. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer (Phila) 1999;86:126–134.PubMedGoogle Scholar
  289. 290.
    Hidalgo M, Hornedo J, Lumbreras C, et al. Outpatient therapy with oral ciprofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial. Cancer (Phila) 1999;85:213–219.PubMedGoogle Scholar
  290. 291.
    Innes HE, Smith DB, O’Reilly SM, Clark PI, Kelly V, Marshall E. Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. Br J Cancer 2003;89:43–49.PubMedGoogle Scholar
  291. 292.
    Petrilli AS, Dantas LS, Campos MC, Tanaka C, Ginani VC, Seber A. Oral ciprofloxacin vs. intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low-risk pediatric oncology patients: randomized prospective trial. Med Pediatr Oncol 2000;34:87–91.PubMedGoogle Scholar
  292. 293.
    Freifeld A, Marchigiani D, Walsh T, et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 1999;341:305–311.PubMedGoogle Scholar
  293. 294.
    Kern WV, Cometta A, De Bock R, Langenaeken J, Paesmans M, Gaya H. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1999;341:312–318.PubMedGoogle Scholar
  294. 295.
    Engervall P, Gunther G, Ljungman P, et al. Trimethoprim-sulfamethoxazole plus amikacin versus ceftazidime monotherapy as empirical treatment in patients with neutropenia and fever. Scand J Infect Dis 1996;28:297–303.PubMedGoogle Scholar
  295. 296.
    Velasco E, Costa MA, Martins CA, Nucci M. Randomized trial comparing oral ciprofloxacin plus penicillin V with amikacin plus carbenicillin or ceftazidime for empirical treatment of febrile neutropenic cancer patients. Am J Clin Oncol 1995;18:429–435.PubMedGoogle Scholar
  296. 297.
    Malik IA, Abbas Z, Karim M. Randomised comparison of oral ciprofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients. Lancet 1992;339:1092–1096.PubMedGoogle Scholar
  297. 298.
    Rubenstein EB, Rolston K, Benjamin RS, et al. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer (Phila) 1993;71:3640–3646.PubMedGoogle Scholar
  298. 299.
    Johnson PR, Liu Yin JA, Tooth JA. A randomized trial of high-dose ciprofloxacin versus azlocillin and netilmicin in the empirical therapy of febrile neutropenic patients. J Antimicrob Chemother 1992;30:203–214.PubMedGoogle Scholar
  299. 300.
    Flaherty JP, Waitley D, Edlin B, et al. Multicenter, randomized trial of ciprofloxacin plus azlocillin versus ceftazidime plus amikacin for empiric treatment of febrile neutropenic patients. Am J Med 1989;87:278S–282S.PubMedGoogle Scholar
  300. 301.
    Chan CC, Oppenheim BA, Anderson H, Swindell R, Scarffe JH. Randomized trial comparing ciprofloxacin plus netilmicin versus piperacillin plus netilmicin for empiric treatment of fever in neutropenic patients. Antimicrob Agents Chemother 1989;33:87–91.PubMedGoogle Scholar
  301. 302.
    Rolston KVI, Rubenstein E, Elting L. Ambulatory management of febrile episodes in low-risk patients. In: 35th InterScience Conference of Antimicrobial Agents and Chemotherapy, 1995, San Francisco, California.Google Scholar
  302. 303.
    Cometta A, Zinner S, de Bock R, et al. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother 1995;39:445–452.PubMedGoogle Scholar
  303. 304.
    Cometta A, Calandra T, Gaya H, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto Infection Program. Antimicrob Agents Chemother 1996;40:1108–1115.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • Nasia Safdar
    • 1
  • Christopher J. Crnich
    • 2
  • Dennis G. Maki
    • 1
  1. 1.Section of Infectious Diseases, Department of MedicineUniversity of Wisconsin Medical SchoolMadisonUSA
  2. 2.Section of Infectious Diseases, Department of MedicineUniversity of WisconsinMadisonUSA

Personalised recommendations